Research Article

Effect of FOXP3 gene variants on the immune-active HBV and inactive HBV phases

Volume: 46 Number: 4 December 30, 2021
TR EN

Effect of FOXP3 gene variants on the immune-active HBV and inactive HBV phases

Abstract

Purpose: FOXP3 gene rs2232365 A/G and the rs3761548 A/C polymorphisms were associated with immune system-related diseases such as Hepatitis B virus (HBV) infection. The function of Treg cells which act as immune-suppressors in the control of HBV-related liver inflammation may be affected by these polymorphisms. The aim of the present study was to evaluate the association between these polymorphisms with HBV infection phases. Materials and Methods: The current study examined the FOXP3 gene polymorphisms in 116 patients with immune-active hepatitis B phase and in 116 individuals with inactive hepatitis B phase by a real-time polymerase chain reaction (RT-PCR). Results: In females, the A allele and AA genotype of rs2232365 polymorphism was not statistically significant although it increased 1.28- and 1.67-fold immune-active HBV risk. Although the G allele of rs2232365 polymorphism increased 1.69-fold immune active HBV risk, it was not statistically significant in males, either. Likewise, the rs3761548 polymorphism could not reach a statistically significant value in males and females, either. Conclusion: This research is to demonstrate the relation between phases of HBV infection and polymorphisms of the FOXP3 gene in the Turkish population. The results of this study showed that there is no effect of these polymorphisms on the immune-active phase of HBV, even though it increased immune-active HBV.

Keywords

FOXP3 , rs2232365 , rs3761548 , immune-active HBV , inactive HBV

References

  1. 1. Png E, Thalamuthu A, Ong RT, Snippe H, Boland GJ, Seielstad M. A genome-wide association study of hepatitis B vaccine response in an Indonesian population reveals multiple independent risk variants in the HLA region. Hum Mol Genet 2011; 20: 3893-8.
  2. 2. Croagh CM, Lubel JS. Natural history of chronic hepatitis B: phases in a complex relationship. World J Gastroenterol. 2014; 20: 10395–404.
  3. 3. Sharifi Z. Natural history of chronic hepatitis B virus infection based on laboratory testing. Iran J Public Health. 2014; 43: 990–3.
  4. 4. Aspinall EJ, Hawkins G, Fraser A, Hutchinson SJ, Goldberg D. Hepatitis B prevention, diagnosis, treatment and care: a review. Occup Med. 2011; 61: 531–40.
  5. 5. Hu L, Zhai X, Liu J, Chu M, Pan S, Jiang J et al. Genetic variants in human leukocyte antigen/DP-DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development. Hepatology 2012; 55: 1426-31. 6. Wong DK, Watanabe T, Tanaka Y, Seto WK, Lee CK, Fung J et al. Role of HLA-DP polymorphisms on chronicity and disease activity of hepatitis B infection in Southern Chinese. PLoS One 2013; 8: e66920.
  6. 7. Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology. 2005; 41: 771-778.
  7. 8. Pereira LMS, Gomes STM, Ishak R, Vallinoto ACR. Regulatory T Cell and Forkhead Box Protein 3 as Modulators of Immune Homeostasis. Front Immunol. 2017; 8: 605. doi:10.3389/fimmu.2017.00605.
  8. 9. Kryczek I, Liu R, Wang G, Wu K, Shu X, Szeliga W et al. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res. 2009; 69(9): 3995-4000. doi: 10.1158/0008-5472.CAN-08-3804.
  9. 10. Lord JD. Promises and Paradoxes of Regulatory T Cells in Inflammatory Bowel Disease. World J Gastroenterol. 2015; 21(40): 11236-45.
  10. 11. Jafarzadeh A, Jamali M, Mahdavi R, Ebrahimi HA, Hajghani H, Khosravimashizi A et al. Circulating levels of interleukin-35 in patients with multiple sclerosis: evaluation of the influences of FOXP3 gene polymorphism and treatment program. Journal of Molecular Neuroscience. 2015; 55(4): 891-7. doi: 10.1007/s12031-014-0443-z.
MLA
Akgöllü, Ersin. “Effect of FOXP3 Gene Variants on the Immune-Active HBV and Inactive HBV Phases”. Cukurova Medical Journal, vol. 46, no. 4, Dec. 2021, pp. 1485-92, doi:10.17826/cumj.978353.